Maggie Cheang, Ph.D., joined the Veracyte Scientific and Technology Advisory Board in June 2026.
Dr. Cheang is an internationally recognized leader in translational cancer biomarker science, molecular pathology, clinical trial design and trial-integrated analytics. She is the Group Leader of Integrative Genomic Analysis in Clinical Trials at The Institute of Cancer Research (ICR), London, where she leads multidisciplinary programs integrating molecular pathology, genomics, artificial intelligence, biostatistics, and experimental medicine to accelerate precision oncology.
Her research bridges discovery science and clinical implementation by converting complex genomic, transcriptomic, immune, and spatial biology data into clinically actionable evidence. She co-developed the PAM50 molecular classifier, which underpins the clinically validated Prosigna® test used worldwide to assess recurrence risk and guide treatment decisions in breast cancer. Dr. Cheang has developed multiple patented molecular classifiers and biomarker frameworks that inform treatment response and are being evaluated in major clinical programs.
She has authored more than 100 peer-reviewed publications and serves on national and international scientific committees, editorial boards, and funding panels, advising on biomarker science, clinical trial methodology, molecular diagnostics, and translational analytics.
Dr. Cheang received her Ph.D. in Pathology from the University of British Columbia and was a Postdoctoral Fellow at University of North Carolina, Chapel Hill.